ATRA时代急性早幼粒细胞白血病诱导治疗期间致命性出血的决定因素
该研究汇总5项含全反式维甲酸(ATRA)诱导方案的临床试验,分析995例急性早幼粒细胞白血病(APL)患者,诱导后30天内出血性死亡(HD)累积发生率为3.7%(95%CI 2.6%-5.0%)。多因素Cox回归显示,白细胞计数≥20000/μL相比<20000/μL的HD风险比为5.20(95%CI 2.70-10.02),ECOG体能状态3-4相比0-2的风险比为2.17(95%CI 0.84-5.62)。
要点
- 诱导后30天内出血性死亡累积发生率为3.7%(95%CI 2.6%-5.0%)。
- 白细胞计数≥20000/μL相比<20000/μL,30天内出血性死亡HR为5.20(95%CI 2.70-10.02)。
- ECOG体能状态3-4相比0-2,30天内出血性死亡HR为2.17(95%CI 0.84-5.62)。
核心结论
- 在高白细胞计数的APL患者中,高白细胞计数是早期出血性死亡的独立预测因素。
研究设计与样本
- 汇总5项含ATRA诱导方案的临床试验(ALLG APML3、ALLG APML4、CALGB C9710、ECOG-ACRIN E2491、SWOG S0521),原始试验共纳入1009例患者,其中995例数据充分进入多因素分析。
主要发现
- 最终队列中诱导后30天内出血性死亡37例,估计累积发生率为3.7%(95%CI 2.6%-5.0%)。
- 多因素Cox回归显示,ECOG体能状态3-4相比0-2的30天内出血性死亡HR为2.17(95%CI 0.84-5.62)。
- 白细胞计数≥20000/μL相比<20000/μL的30天内出血性死亡HR为5.20(95%CI 2.70-10.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute promyelocytic leukemia (APL) is commonly complicated by a complex coagulopathy. Uncertainty remains as to which markers of bleeding risk are independent predictors. Drawing from 5 large clinical trials that included all-trans retinoic acid (ATRA) as part of induction, we assessed known determinants of bleeding at baseline and evaluated them as potential predictors of hemorrhagic death (HD) in the first 30 days of treatment. The studies included were ALLG APML3 (single arm of ATRA + idarubicin ± prednisone), ALLG APML4 (single arm of ATRA + idarubicin + arsenic trioxide + prednisone), CALGB C9710 (single arm of ATRA + cytarabine + daunorubicin), Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2491 (intergroup I0129, consisting of daunorubicin + cytarabine vs ATRA), and SWOG S0521 (single-arm induction of ATRA + cytarabine + daunorubicin). A total of 1009 patients were included in the original trials, of which 995 had sufficient data to be included in our multivariate analysis. In this final cohort, there were 37 HD cases during the first 30 days following induction, for an estimated cumulative incidence of 3.7% (95% confidence interval [CI], 2.6% to 5.0%). Using multivariate Cox proportional hazards regression, the hazard ratio of HD in the first 30 days was 2.17 (95% CI, 0.84-5.62) for an ECOG performance status of 3-4 vs 0-2 and 5.20 (95% CI, 2.70-10.02) for a white blood cell count of ≥20 000/μL vs <20 000/μL. In this large cohort of APL patients, high white blood cell count emerged as an independent predictor of early HD.
引用
- Mantha S, Goldman DA, Devlin SM, et al. Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood. 2017. PMID: 28082441. doi:10.1182/blood-2016-10-747170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。